Imatinib Desensitization After a Type IV Hypersensitivity Reaction in a Gastrointestinal Stromal Tumor Patient—A Case Report

Imatinib Desensitization After a Type IV Hypersensitivity Reaction in a Gastrointestinal Stromal Tumor Patient—A Case Report

ABSTRACT Background Imatinib treatment is approved for several indications, including chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GIST). Although adverse events are common, hypersensitivity reactions are not. Because there is a clear clinical benefit of imatinib treatment, re...

Full description

Saved in:
Bibliographic Details
Main Authors: Maud B. A. van derKleij, Tristan V. M. Bruijn, Raween W. Kalicharan, Yannick S. Elshot, Maxime C. F. Pilon, Mark Oostdijk, Matthijs M. Tibben, Bastiaan Nuijen, Alwin D. R. Huitema, Thomas Rustemeyer, Neeltje Steeghs
Format: Article
Language:English
Published: Wiley 2025-06-01
Series:Cancer Reports
Subjects:
case report
desensitization
gastrointestinal stromal tumor
imatinib
type IV hypersensitivity reaction
Online Access:https://doi.org/10.1002/cnr2.70238
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1002/cnr2.70238

Similar Items